Sign in
Taking people in United StatesPhase 2

Low-dose semaglutide to keep weight off in people living with HIV

Tests low-dose semaglutide after weight loss in adults living with HIV.

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston, United StatesSee the site
Trial code
Registry title
Incretin Microdosing for Cardiometabolic Health in People With HIV
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
12 Feb 2026
Expected to end
30 Jun 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly
  • Dose escalation to 2 mg semaglutide weekly then no semaglutide
Record updated
18 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults living with HIV-1 who take HIV medicines and have a higher body weight. It tests semaglutide weekly injections for weight.

Age
18 years or older
Sex
All sexes can join
Disease stage
HIV-1 with viral load below 200 copies/mL. BMI 30 kg/m2 or more, or 27 kg/m2 or more with at least 1 weight-related health problem.
Earlier treatment
On antiretroviral therapy for at least 24 weeks, with no change in the 12 weeks before entry. Stable doses of anti-inflammatory, blood pressure, lipid or glucose medicines for at least 12 weeks.
Biomarker or test result
HIV-1 RNA below 200 copies/mL at screening. TSH between 0.5 and 10 mIU/L.

Main reasons for not taking part

  • Diabetes or treatment for diabetes
  • Weight of 400 pounds (181 kg) or more, or unexplained weight change of 5% or more in the last 12 weeks
  • Medicines for obesity, or prior weight-loss or stomach surgery
  • Pregnancy, nursing, or plans for either
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

This trial only enrols participants living with HIV. The registry sentence this rests on: Confirmed human immunodeficiency virus type 1 (HIV-1)

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Confirmed human immunodeficiency virus type 1 (HIV-1)
  • On antiretroviral therapy (ART) for greater than or equal to 24 weeks prior to entry and no change in regimen in the 12 weeks prior to entry or planned change for the study duration
  • HIV-1 ribonucleic acid (RNA) <200 copies/mL at screening
  • BMI greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 if also with greater than or equal to 1 weight-related comorbidity
  • If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for greater than or equal to 12 weeks prior to entry and no plans to dose escalate for the study duration
  • All participants must be willing and able to provide written informed consent and undergo all required study procedures

Who cannot take part

  • Weight greater than or equal to 400 pounds [due to dual X-ray absorptiometry (DXA) machine limitations] or unexplained weight change greater than or equal to 5% in the 12 weeks prior to entry
  • Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period
  • Use of human growth hormone, tesamorelin or anabolic steroids <12 weeks prior to entry, unless on a stable dose for >24 weeks prior to entry, or plans to start any of these medications while on study
  • Prior bariatric surgery or major gastric surgery or plans for weight reduction surgery while on study
  • Untreated, poorly controlled or previously undiagnosed thyroid disease
  • Poorly controlled or previously undiagnosed thyroid disease, defined as thyroid-stimulating hormone (TSH) <0.5 or >10 milli-international units per liter (mIU/L) at screening
  • Active drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements
  • Use of planned use of any immunomodulatory therapy HIV vaccine, investigational therapy or tumor necrosis factor (TNF-α) therapy during the study period
  • Diagnosis of or on treatment for diabetes mellitus (stable metformin dosing for pre-diabetes not excluded)
  • Active eating disorder
  • Personal or first-degree relative history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
  • Known allergy/sensitivity to Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)
  • Current serious illness requiring systemic treatment and/or hospitalization, in the opinion of site investigator
  • Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period
  • Active, severe delayed gastric emptying
  • Known retinopathy
  • Chronic pancreatitis
  • Pregnancy, nursing or plans for either during the study period

Where in United States

  • The University of Texas Health Science Center at HoustonHouston, United StatesContact: Jordan E Lake, MD, MScTaking people

About the trial

What the trial wants to find out

The objectives of this study are as follows:

Read full original descriptionShow less

Primary Objective

* To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy.

Secondary Objectives

* To evaluate the tolerability of semaglutide microdosing in adults with HIV. * To evaluate changes in weight, waist circumference (WC) and body mass index (BMI) over 12 weeks (W) of semaglutide weight loss induction and 48 W of semaglutide microdosing therapy.

The 2 groups in the trial

  • Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weeklyTreatment being tested

    Participants will initiate semaglutide at 0.25 milligrams (mg) subcutaneously per week with dose titration up to 2.0 mg subcutaneously per week, over a total of 12 weeks. Dose titration will occur as follows: 0.25 mg weekly for 2 weeks, then 0.5 mg weekly for 2 weeks, then 1 mg weekly for 4 weeks, then 2.0 mg weekly for 4 weeks. Then, participants in this arm will receive microdosing with semaglutide at 0.5 mg subcutaneously every week during weeks 13-60.

  • Dose escalation to 2 mg semaglutide weekly then no semaglutideTreatment being tested

    Participants will initiate semaglutide at 0.25 milligrams (mg) subcutaneously per week with dose titration up to 2.0 mg subcutaneously per week, over a total of 12 weeks. Dose titration will occur as follows: 0.25 mg weekly for 2 weeks, then 0.5 mg weekly for 2 weeks, then 1 mg weekly for 4 weeks, then 2.0 mg weekly for 4 weeks. Then, participants in this arm will receive no semaglutide during weeks 13-60.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Incretin Microdosing for Cardiometabolic Health in People With HIV: The REINFORCE Trial
Plain-language title
Low-dose semaglutide to keep weight off in people living with HIVGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
18 February 2026